Symbols / SNDX Stock $20.41 -4.54% Syndax Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NMS
SNDX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael A. Metzger M.B.A.
Exch · Country NMS · United States
Market Cap 1.81B
Enterprise Value 1.79B
Income -243.25M
Sales 217.17M
FCF (ttm) -186.26M
Book/sh 0.74
Cash/sh 4.08
Employees 298
Insider 10d —
IPO Mar 02, 2016
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -118.44
PEG —
P/S 8.33
P/B 27.62
P/C —
EV/EBITDA -8.00
EV/Sales 8.25
Quick Ratio 4.90
Current Ratio 5.47
Debt/Eq 829.75
LT Debt/Eq —
EPS (ttm) -2.79
EPS next Y -0.17
EPS Growth —
Revenue Growth 223.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-04-30
Earnings (prior) 2026-04-30
ROA -25.17%
ROE -189.53%
ROIC —
Gross Margin -23.17%
Oper. Margin -52.73%
Profit Margin -112.01%
Shs Outstand 88.61M
Shs Float 75.10M
Insider Own 1.72%
Instit Own 116.30%
Short Float 22.86%
Short Ratio 12.85
Short Interest 19.91M
52W High 25.59
vs 52W High -20.24%
52W Low 8.58
vs 52W Low 137.88%
Beta 0.41
Impl. Vol. 3.13%
Rel Volume 0.74
Avg Volume 1.55M
Volume 1.14M
Target (mean) $39.25
Tgt Median $37.00
Tgt Low $29.00
Tgt High $57.00
# Analysts 12
Recom Strong_buy
Prev Close $21.38
Price $20.41
Change -4.54%
About

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$39.25
Mean price target
2. Current target
$20.41
Latest analyst target
3. DCF / Fair value
$-37.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$20.41
Low
$29.00
High
$57.00
Mean
$39.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-01 main Barclays Overweight → Overweight $37
2026-04-01 main Goldman Sachs Buy → Buy $34
2026-03-31 main Mizuho Outperform → Outperform $43
2026-03-09 main JP Morgan Overweight → Overweight $45
2026-03-02 main Citigroup Buy → Buy $57
2025-12-09 reit BTIG Buy → Buy $56
2025-11-24 main Barclays Overweight → Overweight $35
2025-11-12 main JP Morgan Overweight → Overweight $33
2025-11-04 main UBS Buy → Buy $38
2025-11-04 main Barclays Overweight → Overweight $22
2025-10-27 reit HC Wainwright & Co. Buy → Buy $40
2025-10-27 reit BTIG Buy → Buy $56
2025-09-19 reit BTIG Buy → Buy $56
2025-09-05 main Goldman Sachs Buy → Buy $24
2025-09-04 init Guggenheim — → Buy $34
2025-08-05 main Citigroup Buy → Buy $51
2025-08-05 main BTIG Buy → Buy $56
2025-07-15 main UBS Buy → Buy $35
2025-07-10 init Goldman Sachs — → Buy $18
2025-05-06 main Scotiabank Sector Perform → Sector Perform $17
News
RSS: Latest SNDX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-09 GOLDAN KEITH ALAN Chief Financial Officer — 3,410 $21.03 $71,705
2026-02-09 METZGER MICHAEL A Chief Executive Officer — 17,159 $21.03 $360,819
2026-02-06 GOLDAN KEITH ALAN Chief Financial Officer — 2,082 $20.62 $42,931
2026-02-06 METZGER MICHAEL A Chief Executive Officer — 7,412 $20.62 $152,835
2026-02-04 PODLESAK DENNIS G Director — 48,000 $0.00 $0
2026-02-04 KATKIN KEITH A Director — 24,000 $0.00 $0
2026-02-04 LEGAULT PIERRE Director — 24,000 $0.00 $0
2026-02-04 GOLDAN KEITH ALAN Chief Financial Officer — 52,250 $0.00 $0
2026-02-04 METZGER MICHAEL A Chief Executive Officer — 217,600 $0.00 $0
2026-02-04 HUBER MARTIN H JR Director — 24,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
172.35
+627.84%
23.68
0.00
0.00
Operating Revenue
172.35
+627.84%
23.68
0.00
0.00
Cost Of Revenue
6.97
+743.83%
0.83
0.00
0.00
Reconciled Cost Of Revenue
6.97
+743.83%
0.83
0.00
0.00
Gross Profit
165.38
+623.65%
22.85
0.00
0.00
Operating Expense
438.47
+20.95%
362.53
+57.65%
229.95
+51.53%
151.76
Research And Development
258.78
+7.09%
241.65
+48.22%
163.03
+37.58%
118.50
Selling General And Administration
179.68
+48.65%
120.88
+80.63%
66.92
+101.22%
33.26
General And Administrative Expense
179.68
+48.65%
120.88
+80.63%
66.92
+101.22%
33.26
Salaries And Wages
102.74
+46.81%
69.98
+76.28%
39.70
—
Other Gand A
76.94
+51.18%
50.89
+86.97%
27.22
-18.16%
33.26
Total Expenses
445.44
+22.59%
363.35
+58.01%
229.95
+51.53%
151.76
Operating Income
-273.08
+19.60%
-339.67
-47.71%
-229.95
-51.53%
-151.76
Total Operating Income As Reported
-273.08
+19.60%
-339.67
-47.71%
-229.95
-51.53%
-151.76
EBITDA
-251.63
+19.82%
-313.82
-50.05%
-209.14
-43.08%
-146.17
Normalized EBITDA
-251.63
+19.82%
-313.82
-50.05%
-209.14
-43.08%
-146.17
Reconciled Depreciation
0.01
-25.00%
0.01
-33.33%
0.01
-63.64%
0.03
EBIT
-251.64
+19.82%
-313.83
-50.05%
-209.15
-43.06%
-146.20
Net Income
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Pretax Income
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Net Non Operating Interest Income Expense
-11.05
-152.24%
21.16
+0.98%
20.95
+666.18%
2.73
Interest Expense Non Operating
33.78
+585.29%
4.93
+2270.19%
0.21
-93.37%
3.14
Net Interest Income
-11.05
-152.24%
21.16
+0.98%
20.95
+666.18%
2.73
Interest Expense
33.78
+585.29%
4.93
+2270.19%
0.21
-93.37%
3.14
Interest Income Non Operating
22.73
-12.88%
26.09
+23.29%
21.16
+260.41%
5.87
Interest Income
22.73
-12.88%
26.09
+23.29%
21.16
+260.41%
5.87
Other Income Expense
-1.28
-419.43%
-0.25
+31.58%
-0.36
-14.24%
-0.32
Other Non Operating Income Expenses
-1.28
-419.43%
-0.25
+31.58%
-0.36
-14.24%
-0.32
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Net Income From Continuing Operation Net Minority Interest
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Net Income From Continuing And Discontinued Operation
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Net Income Continuous Operations
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Normalized Income
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Net Income Common Stockholders
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Otherunder Preferred Stock Dividend
—
—
—
0.00
Diluted EPS
-3.29
+11.56%
-3.72
-24.83%
-2.98
-21.14%
-2.46
Basic EPS
-3.29
+11.56%
-3.72
-24.83%
-2.98
-21.14%
-2.46
Basic Average Shares
86.63
+1.17%
85.62
+21.67%
70.37
+15.82%
60.76
Diluted Average Shares
86.63
+1.17%
85.62
+21.67%
70.37
+15.82%
60.76
Diluted NI Availto Com Stockholders
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
529.71
-26.92%
724.82
+18.26%
612.88
+23.26%
497.24
Current Assets
528.08
-12.43%
603.06
+3.82%
580.88
+18.60%
489.79
Cash Cash Equivalents And Short Term Investments
413.69
-29.03%
582.91
+0.92%
577.58
+19.24%
484.40
Cash And Cash Equivalents
134.93
-12.43%
154.08
-47.84%
295.39
+297.27%
74.36
Cash Equivalents
134.93
-12.43%
154.08
-47.84%
295.39
+297.27%
74.36
Other Short Term Investments
278.76
-35.00%
428.83
+51.97%
282.19
-31.18%
410.04
Receivables
70.29
+406.75%
13.87
+1030.48%
1.23
-69.76%
4.06
Accounts Receivable
38.00
+399.82%
7.60
0.00
-100.00%
3.47
Other Receivables
30.15
+729.41%
3.63
—
—
Accrued Interest Receivable
2.15
-18.53%
2.63
+114.67%
1.23
+110.46%
0.58
Inventory
32.75
+8849.18%
0.37
0.00
—
Raw Materials
29.03
0.00
0.00
—
Work In Process
2.11
+540.00%
0.33
0.00
—
Finished Goods
1.61
+4386.11%
0.04
0.00
—
Prepaid Assets
10.13
+91.33%
5.29
+164.35%
2.00
+64.86%
1.22
Restricted Cash
—
—
—
0.00
Other Current Assets
1.22
+99.18%
0.61
+871.43%
0.06
-46.15%
0.12
Total Non Current Assets
1.62
-98.67%
121.76
+280.45%
32.00
+329.58%
7.45
Net PPE
1.52
-24.68%
2.02
+35.25%
1.50
+41.17%
1.06
Gross PPE
1.95
-20.20%
2.44
+28.07%
1.91
+30.73%
1.46
Accumulated Depreciation
-0.42
-1.43%
-0.42
-1.95%
-0.41
-3.01%
-0.40
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.17
+0.00%
0.17
+0.00%
0.17
+0.00%
0.17
Other Properties
1.61
-23.41%
2.11
+34.05%
1.57
+39.89%
1.12
Leases
0.17
+0.00%
0.17
+0.00%
0.17
+0.00%
0.17
Investments And Advances
0.00
-100.00%
119.52
+300.68%
29.83
+445.42%
5.47
Other Non Current Assets
0.10
-53.00%
0.22
-68.09%
0.68
-26.25%
0.92
Total Liabilities Net Minority Interest
465.08
+6.50%
436.69
+644.14%
58.68
+97.01%
29.79
Current Liabilities
120.12
+16.00%
103.55
+78.24%
58.10
+99.88%
29.07
Payables And Accrued Expenses
84.76
+12.71%
75.21
+67.17%
44.99
+103.78%
22.08
Payables
23.95
-23.14%
31.16
+81.26%
17.19
+295.24%
4.35
Accounts Payable
16.58
+42.61%
11.63
+16.72%
9.96
+128.99%
4.35
Other Payable
7.37
-62.27%
19.54
+170.16%
7.23
—
Current Accrued Expenses
60.81
+38.07%
44.04
+58.45%
27.80
+56.80%
17.73
Pensionand Other Post Retirement Benefit Plans Current
24.35
+68.21%
14.48
+29.58%
11.17
+87.92%
5.95
Current Debt And Capital Lease Obligation
0.47
-96.25%
12.60
+1103.06%
1.05
+138.50%
0.44
Current Debt
—
12.12
—
—
Other Current Borrowings
—
12.12
—
—
Current Capital Lease Obligation
0.47
-1.67%
0.48
-54.15%
1.05
+138.50%
0.44
Current Deferred Liabilities
—
—
—
—
Current Deferred Revenue
—
—
—
—
Other Current Liabilities
10.53
+729.21%
1.27
+43.02%
0.89
+47.02%
0.60
Total Non Current Liabilities Net Minority Interest
344.96
+3.55%
333.14
+56556.97%
0.59
-18.56%
0.72
Long Term Debt And Capital Lease Obligation
344.96
+3.55%
333.14
+56556.97%
0.59
-18.56%
0.72
Long Term Debt
343.91
+3.72%
331.56
—
—
Long Term Capital Lease Obligation
1.05
-33.40%
1.58
+168.37%
0.59
-18.56%
0.72
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Revenue
—
—
—
—
Stockholders Equity
64.63
-77.57%
288.12
-48.01%
554.20
+18.56%
467.45
Common Stock Equity
64.63
-77.57%
288.12
-48.01%
554.20
+18.56%
467.45
Capital Stock
0.01
+0.00%
0.01
+12.50%
0.01
+14.29%
0.01
Common Stock
0.01
+0.00%
0.01
+12.50%
0.01
+14.29%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
87.41
+2.00%
85.69
+1.02%
84.83
+24.54%
68.11
Ordinary Shares Number
87.41
+2.00%
85.69
+1.02%
84.83
+24.54%
68.11
Additional Paid In Capital
1,570.75
+4.08%
1,509.11
+3.62%
1,456.37
+25.41%
1,161.29
Retained Earnings
-1,506.58
-23.37%
-1,221.16
-35.32%
-902.40
-30.21%
-693.04
Gains Losses Not Affecting Retained Earnings
0.45
+177.30%
0.16
-25.23%
0.22
+127.05%
-0.81
Other Equity Adjustments
0.45
+177.30%
0.16
-25.23%
0.22
+127.05%
-0.81
Total Equity Gross Minority Interest
64.63
-77.57%
288.12
-48.01%
554.20
+18.56%
467.45
Total Capitalization
408.54
-34.07%
619.69
+11.82%
554.20
+18.56%
467.45
Working Capital
407.96
-18.33%
499.51
-4.45%
522.78
+13.47%
460.72
Invested Capital
408.54
-35.34%
631.80
+14.00%
554.20
+18.56%
467.45
Total Debt
345.43
-0.09%
345.74
+21046.12%
1.64
+40.83%
1.16
Net Debt
208.98
+10.22%
189.60
—
—
Capital Lease Obligations
1.52
-26.00%
2.06
+25.87%
1.64
+40.83%
1.16
Net Tangible Assets
64.63
-77.57%
288.12
-48.01%
554.20
+18.56%
467.45
Tangible Book Value
64.63
-77.57%
288.12
-48.01%
554.20
+18.56%
467.45
Available For Sale Securities
—
119.52
+300.68%
29.83
—
Interest Payable
25.52
+417.57%
4.93
0.00
—
Investmentin Financial Assets
0.00
-100.00%
119.52
+300.68%
29.83
—
Notes Receivable
—
—
—
3.47
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-322.98
-17.49%
-274.90
-71.17%
-160.60
-20.14%
-133.68
Cash Flow From Continuing Operating Activities
-322.98
-17.49%
-274.90
-71.17%
-160.60
-20.14%
-133.68
Net Income From Continuing Operations
-285.42
+10.46%
-318.76
-52.25%
-209.36
-40.19%
-149.34
Depreciation Amortization Depletion
0.01
-25.00%
0.01
-33.33%
0.01
-63.64%
0.03
Depreciation
0.01
-25.00%
0.01
-33.33%
0.01
-63.64%
0.03
Depreciation And Amortization
0.01
-25.00%
0.01
-33.33%
0.01
-63.64%
0.03
Other Non Cash Items
1.34
+31.21%
1.02
+37.89%
0.74
-51.51%
1.52
Stock Based Compensation
47.50
+10.41%
43.03
+39.01%
30.95
+93.21%
16.02
Provisionand Write Offof Assets
3.67
0.00
0.00
—
Operating Gains Losses
—
—
—
-0.19
Gain Loss On Investment Securities
—
—
—
-0.19
Change In Working Capital
-79.32
-697.72%
13.27
-58.35%
31.86
+1823.91%
1.66
Change In Receivables
-79.81
-10573.23%
0.76
-92.88%
10.71
0.00
Changes In Account Receivables
-30.39
-299.82%
-7.60
0.00
0.00
Change In Inventory
-32.09
-8668.03%
-0.37
0.00
0.00
Change In Prepaid Assets
-14.54
-73.26%
-8.39
-1341.57%
0.68
+122.75%
-2.97
Change In Payables And Accrued Expense
47.12
+126.50%
20.80
+1.59%
20.48
+152.75%
8.10
Change In Accrued Expense
42.17
+120.32%
19.14
+28.73%
14.87
+57.81%
9.42
Change In Payable
4.95
+197.54%
1.67
-70.33%
5.61
+525.40%
-1.32
Change In Account Payable
4.95
+197.54%
1.67
-70.33%
5.61
+525.40%
-1.32
Change In Other Working Capital
—
12.00
+12.08%
10.71
+408.18%
-3.47
Change In Other Current Assets
0.00
-100.00%
0.46
0.00
0.00
Investing Cash Flow
290.04
+231.97%
-219.78
-286.87%
117.61
+163.17%
-186.19
Cash Flow From Continuing Investing Activities
290.04
+231.97%
-219.78
-286.87%
117.61
+163.17%
-186.19
Net PPE Purchase And Sale
-0.19
0.00
0.00
-100.00%
0.23
Purchase Of PPE
-0.19
0.00
0.00
0.00
Sale Of PPE
—
0.00
0.00
-100.00%
0.23
Capital Expenditure
-0.19
—
—
—
Net Investment Purchase And Sale
290.22
+232.05%
-219.78
-286.87%
117.61
+163.09%
-186.41
Purchase Of Investment
-195.81
+64.85%
-557.05
-57.09%
-354.61
+28.41%
-495.35
Sale Of Investment
486.03
+44.10%
337.28
-28.58%
472.21
+52.85%
308.93
Financing Cash Flow
13.68
-96.13%
353.37
+33.78%
264.13
+53.34%
172.25
Cash Flow From Continuing Financing Activities
13.68
-96.13%
353.37
+33.78%
264.13
+53.34%
172.25
Net Issuance Payments Of Debt
—
0.00
0.00
+100.00%
-21.00
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
0.00
0.00
+100.00%
-21.00
Long Term Debt Issuance
—
—
—
0.00
Long Term Debt Payments
—
0.00
0.00
+100.00%
-21.00
Net Long Term Debt Issuance
—
0.00
0.00
+100.00%
-21.00
Net Common Stock Issuance
0.00
0.00
-100.00%
258.09
+42.29%
181.39
Proceeds From Stock Option Exercised
13.68
+40.77%
9.71
+60.90%
6.04
-49.09%
11.86
Net Other Financing Charges
—
343.65
—
—
Changes In Cash
-19.27
+86.36%
-141.31
-163.90%
221.14
+249.81%
-147.61
Beginning Cash Position
154.30
-47.80%
295.61
+296.95%
74.47
-66.47%
222.08
End Cash Position
135.03
-12.49%
154.30
-47.80%
295.61
+296.95%
74.47
Free Cash Flow
-323.17
-17.56%
-274.90
-71.17%
-160.60
-20.14%
-133.68
Interest Paid Supplemental Data
13.19
0.00
0.00
-100.00%
2.06
Amortization Of Securities
-10.75
+20.16%
-13.47
+9.02%
-14.80
-337.70%
-3.38
Common Stock Issuance
0.00
0.00
-100.00%
258.09
+42.29%
181.39
Issuance Of Capital Stock
0.00
0.00
-100.00%
258.09
+42.29%
181.39
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category